Related references
Note: Only part of the references are listed.REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial
Maurizio Fava et al.
AMERICAN JOURNAL OF PSYCHIATRY (2022)
Real-world evidence from a European cohort study of patients with treatment resistant depression: Healthcare resource utilization
K. Heerlein et al.
JOURNAL OF AFFECTIVE DISORDERS (2022)
Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry
Hitoshi Sakurai et al.
PHARMACOPSYCHIATRY (2022)
Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents
Mai Watanabe et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2022)
Intravenous arketamine for treatment-resistant depression: open-label pilot study
Gustavo C. Leal et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2021)
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Anees Bahji et al.
JOURNAL OF AFFECTIVE DISORDERS (2021)
Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons
Santosh Pothula et al.
NEUROPSYCHOPHARMACOLOGY (2021)
The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial
Michael Davidson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2021)
A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-d-aspartate receptor blockade in healthy veterans
Nicholas Murphy et al.
NEUROPSYCHOPHARMACOLOGY (2021)
Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials
Amna Majeed et al.
EXPERT OPINION ON EMERGING DRUGS (2021)
TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats
Hiroe Hara et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2021)
Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis
Ashley A. Conley et al.
PSYCHOPHARMACOLOGY (2021)
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation
Patricio O'Donnell et al.
TRANSLATIONAL PSYCHIATRY (2021)
Efficacy and safety of mij821 in patients with treatment-resistant depression: Results from a randomized, placebo-controlled, proof-of-concept study
N. Ghaemi et al.
EUROPEAN PSYCHIATRY (2021)
Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders
Anindya Bhattacharya et al.
NEUROPSYCHOPHARMACOLOGY (2020)
OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females
Mitchell F. Brin et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2020)
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies
Maurizio Fava et al.
MOLECULAR PSYCHIATRY (2020)
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression
Ramakrishna Nirogi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A Randomized Trial of the N-Methyl-D-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression
Lawrence T. Park et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2020)
Esketamine/ketamine for treatment-resistant depression
Acioly L. T. Lacerda
BRAZILIAN JOURNAL OF PSYCHIATRY (2020)
Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents
Molly C. Kalmoe et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)
Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
Angela Arsova et al.
MOLECULAR PHARMACOLOGY (2020)
Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder
Daniel Umbricht et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation
Taro Kato et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Is the HPA Axis as Target for Depression Outdated, or Is There a New Hope?
Andreas Menke
FRONTIERS IN PSYCHIATRY (2019)
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
Michael E. Thase et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study
Mu-Hong Chen et al.
NEUROPSYCHOPHARMACOLOGY (2019)
N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects
Manoela V. Fogaca et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Mechanisms and treatment of late-life depression
George S. Alexopoulos
TRANSLATIONAL PSYCHIATRY (2019)
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems
Samuel T. Wilkinson et al.
DRUG DISCOVERY TODAY (2019)
Discovery of NV-5138, the first selective Brain mTORC1 activator
Shomit Sengupta et al.
SCIENTIFIC REPORTS (2019)
Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)
John M. Zajecka et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2019)
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants
Maarten Timmers et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
A Review of the Mechanism of Antagonism of N-methyl-D-aspartate Receptor by Ketamine in Treatment-resistant Depression
Yasar Sattar et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2018)
Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study
Gerard Sanacora et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial
James W. Murrough et al.
JOURNAL OF AFFECTIVE DISORDERS (2017)
Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder
F. Agbo et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
POSTOPERATIVE ANTICHOLINERGIC POISONING: CONCEALED COMPLICATIONS OF A COMMONLY USED MEDICATION
Xiao Chi Zhang et al.
JOURNAL OF EMERGENCY MEDICINE (2017)
Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of L-4-chlorokynurenine in healthy volunteers
Mark Wallace et al.
SCANDINAVIAN JOURNAL OF PAIN (2017)
Antidepressant-like effects of long-term sarcosine treatment in rats with or without chronic unpredictable stress
Kuang-Ti Chen et al.
BEHAVIOURAL BRAIN RESEARCH (2017)
Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial
Maurizio Fava et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs
Zuleide M. Ignacio et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice
Ewa Poleszak et al.
METABOLIC BRAIN DISEASE (2016)
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Panos Zanos et al.
NATURE (2016)
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Linda Nguyen et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression A Randomized Clinical Trial
Jorge A. Quiroz et al.
JAMA PSYCHIATRY (2016)
A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists
David Stroebel et al.
MOLECULAR PHARMACOLOGY (2016)
Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats
Jeffrey Burgdorf et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Peter Nagele et al.
BIOLOGICAL PSYCHIATRY (2015)
Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent
Sheldon Preskorn et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2015)
Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study
Lesley M. Arnold et al.
JOURNAL OF RHEUMATOLOGY (2015)
THE LONG-LASTING ANTIDEPRESSANT EFFECTS OF RAPASTINEL (GLYX-13) ARE ASSOCIATED WITH A METAPLASTICITY PROCESS IN THE MEDIAL PREFRONTAL CORTEX AND HIPPOCAMPUS
J. Burgdorf et al.
NEUROSCIENCE (2015)
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
C. Yang et al.
TRANSLATIONAL PSYCHIATRY (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition
Panos Zanos et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression
Lothar Lindemann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Kyle A. B. Lapidus et al.
BIOLOGICAL PSYCHIATRY (2014)
Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder
Shiou-Lan Chen et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists
Joseph R. Moskal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS
Tammas Frederick Kelly et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
Using Deuterium in Drug Discovery: Leaving the Label in the Drug
Thomas G. Gant
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial
Eric Finzi et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2014)
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects
G. Sanacora et al.
MOLECULAR PSYCHIATRY (2014)
The Impact of Individual Depressive Symptoms on Impairment of Psychosocial Functioning
Eiko I. Fried et al.
PLOS ONE (2014)
R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Ji-chun Zhang et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2014)
Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression
Chih-Chia Huang et al.
BIOLOGICAL PSYCHIATRY (2013)
A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression
Carlos A. Zarate et al.
BIOLOGICAL PSYCHIATRY (2013)
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression
Uriel Heresco-Levy et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Antidepressant Augmentation Using the N-Methyl-D-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial
Eric G. Smith et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder
Lobna Ibrahim et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2012)
3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders
Massimiliano Bianchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Longitudinal Course of Bipolar I Disorder Duration of Mood Episodes
David A. Solomon et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical Trial
Wayne C. Drevets et al.
BIOLOGICAL PSYCHIATRY (2010)
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
Sanjay J. Mathew et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Rapid Enhancement of Glutamatergic Neurotransmission in Bipolar Depression Following Treatment with Riluzole
Brian P. Brennan et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Postpartum depression
Teri Pearlstein et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression
Brendon Binneman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder
Sheldon H. Preskorn et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Gerard Sanacora et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms
Gerard Sanacora et al.
BIOLOGICAL PSYCHIATRY (2007)
Antidepressant efficacy of the antimuscarinic drug scopolamine - A randomized, placebo-controlled clinical trial
Maura L. Furey et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Uriel Heresco-Levy et al.
JOURNAL OF AFFECTIVE DISORDERS (2006)
Mechanism of action of memantine
JW Johnson et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
A double-blind, placebo-controlled study of memantine in the treatment of major depression
CA Zarate et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression
CA Zarate et al.
BIOLOGICAL PSYCHIATRY (2005)
An open-label trial of riluzole in patients with treatment-resistant major depression
CA Zarate et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
The epidemiology of major depressive disorder - Results from the National Comorbidity Survey Replication (NCS-R).
RC Kessler et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders
MA Frye et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2000)
Share Paper
